{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:39:59Z","timestamp":1761896399987},"reference-count":11,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T00:00:00Z","timestamp":1478044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) is a hematologic malignancy that often results in transfusion dependency and a hypercoagulable state. This rare disease currently lacks formal guidelines for treatment; however, various case reports have demonstrated efficacy in the use of lenalidomide. This immunomodulatory drug has shown promise in patients with 5q deletions, with reports of achieving transfusion independence and normalization of platelet counts. Herein we present the case of a 68-year-old African American woman with RARS-T who tested negative for 5q deletion and JAK2 V617F and MPL W515K\/L mutations. Her treatment with lenalidomide therapy resulted in a five-year durable complete clinical response.<\/jats:p>","DOI":"10.4081\/hr.2016.6592","type":"journal-article","created":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T12:13:55Z","timestamp":1478088835000},"page":"48-50","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis with Lenalidomide in a Patient testing Negative for 5q Deletion and JAK2 V617F and MPL W515K\/L Mutations"],"prefix":"10.3390","volume":"8","author":[{"given":"Ryan","family":"Keen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Pantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Dainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,11,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.24038","article-title":"Refractory anemia with ring sideroblasts and RARS with thrombocytosis","volume":"90","author":"Patnaik","year":"2015","journal-title":"Am J Hematol"},{"key":"ref2","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swederlow","year":"2008"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","article-title":"Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis","volume":"97","author":"Broseus","year":"2012","journal-title":"Haematologica"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.3324\/haematol.2014.119032","article-title":"Refractory anemia with ring sideroblasts and marked thrombocytosis (RARS-T) cases harbor mutations in sf3b1 or other spliceosome genes accompanied by JAK2V617F and asxl1 mutations","volume":"100","author":"Jeromin","year":"2015","journal-title":"Haematologica"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of sf3b1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/leu.2014.49","article-title":"Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"28","author":"Broseus","year":"2014","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","article-title":"Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndrome","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2010-01-263087","article-title":"Efficacy of single-agent lenalidomide in patients with jak2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis","volume":"116","author":"Huls","year":"2010","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3324\/haematol.2009.008508","article-title":"Low RPS14 expression is common in myelodysplastic syndrome and defines a subgroup of patients with prolonged survival","volume":"94","author":"Czibere","year":"2009","journal-title":"Haematologica"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/viewFile\/6592\/6555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2038-8330\/8\/4\/6592\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:09:41Z","timestamp":1645600181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/8\/4\/6592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,2]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,11]]}},"alternative-id":["hr.2016.6592"],"URL":"https:\/\/doi.org\/10.4081\/hr.2016.6592","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,2]]}}}